CORRECTING and REPLACING -- SHAREHOLDER ALERT: Pomerantz

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CORRECTING and REPLACING -- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Impax Laboratories, Inc. of Class Action Lawsuit and Upcoming Deadline -- IPXL

NEW YORK, Oct. 10, 2014 (GLOBE NEWSWIRE) -- In a press release issued on September 29, 2014, by Pomerantz LLP, regarding a class action lawsuit against Impax Laboratories, Inc., the deadline of October 13, 2014 has been updated to October 14, 2014. The full, corrected release follows:

Pomerantz LLP has filed a class action lawsuit against Impax Laboratories, Inc. ("Impax" or the "Company") (Nasdaq: IPXL ) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-03673, is on behalf of a class consisting of all persons or entities who purchased Impax securities between May 20, 2013 and July 28, 2014, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").

If you are a shareholder who purchased Impax securities during the Class Period, you have until October 14, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Impax is a specialty pharmaceutical company engaged in the development, manufacture and marketing of bio-equivalent pharmaceutical products, referred to as generic products, in addition to the development of proprietary branded products. The Company operates in two segments, referred to as the "Global Pharmaceuticals Division" ("Global Division") and the "Impax Pharmaceuticals Division" ("Impax Division").

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the quality control at the Company's Taiwan production facility. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company failed to maintain proper quality control and manufacturing practices at its Taiwan facility in violation of current Good Manufacturing Practices ("cGMP"); (2) the manufacturing deficiencies at the Taiwan facility could have a material adverse impact on the Company's ability to successfully launch its new drug, RYTARY; (3) the manufacturing deficiencies at the Taiwan facility jeopardized the Company's ability to manufacture, sell, and distribute generic pharmaceutical products; and (4) based upon the above, Defendants lacked a reasonable basis for their positive statements about the Company and its outlook, including statements about its ability to launch RYTARY.

On July 29, 2014, Impax announced that the FDA completed an inspection of the Company's Taiwan facility. The FDA's inspection covered two areas. First, it covered a Pre-Approval Inspection for RYTARY, given the critical importance of the Taiwan facility to the manufacturing processes of the Company's drug candidate. Moreover, it included a general good manufacturing practices inspection. Based on its inspection, the FDA issued a Form 483 (a form used by the FDA to document and communicate deficiencies in a company's manufacturing quality-control system), stating that it had found "ten inspectional observations," or deficiencies, at the Taiwan facility.

On this news, the Company's shares fell $4.27, or over 15.23%, to close at $23.76 on July 29, 2014.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com .

Robert S. Willoughby Pomerantz LLP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 115

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 43

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 55

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 123

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 77

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 114

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 100

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 100

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading

Top 5 Most Recently Viewed Articles

Anivive's Lab Expansion: Driving Innovation in Veterinary Diagnostics

Updated Category News Views 130

Expanding Horizons in Veterinary Diagnostics Anivive is embarking on an exciting journey as it expands its state-of-the-art laboratory, a move that reflects the soaring demand for its specialized pathology services. This enhancement comes in response to the growing interest in veterinary diagnostics, particularly through its subsidiary, Vidium, known for its leadership in...

Continue Reading
Aurora Chen Joins PBGH as Vice President to Lead Advisory Services

Updated Category News Views 239

Aurora Chen Joins PBGH as Vice President of Advisory Services PBGH, a notable nonprofit coalition, has proudly announced the appointment of Aurora Chen as its Vice President of Advisory Services. Bringing a wealth of experience in the health care and employee benefits sector, Chen is set to lead efforts that expand and enhance the advisory services offered by PBGH. This...

Continue Reading
What Are the Pros and Cons of Using a Financial Planner?

Updated Category Personal Finance Views 654

Are you considering enlisting the help of a financial planner and aren’t sure if it's the right choice for you? Then you need to know about their pros and cons! Financial planners play a vital role in offering you support and guidance with tailor-made plans that help you meet your savings, retirement, or investment goals. We have outlined the pros and cons of a...

Continue Reading
Angel Oak Financial Strategies Trust Announces March 2025 Dividend

Updated Category News Views 113

Introduction to Angel Oak Financial Strategies Income Term Trust Angel Oak Financial Strategies Income Term Trust (FINS) has declared a monthly distribution that investors eagerly anticipate. The closed-end fund listed on the New York Stock Exchange is making headlines as it announces a distribution of $0.109 per share for March. Understanding the mechanics behind such...

Continue Reading
Investors Eye Value Stocks as Federal Reserve Makes Moves

Updated Category News Views 81

Exploring Value Stocks Amid Federal Adjustments Bank of America has underscored three key sectors that stand to gain from the Federal Reserve's unique dual approach of cutting interest rates while profits rise in corporate sectors. This 'rare double whammy of stimulus' could present a significant opportunity for savvy investors keen on value stocks. Key Sector Highlights...

Continue Reading